Holen Sie sich die Stockscreener-App
33.28
1.45%
-0.49
Schlusskurs vom Vortag:
$33.77
Offen:
$33.87
24-Stunden-Volumen:
770.60K
Relative Volume:
0.96
Marktkapitalisierung:
$1.93B
Einnahmen:
$899.11M
Nettoeinkommen (Verlust:
$145.62M
KGV:
13.40
EPS:
2.4829
Netto-Cashflow:
$322.54M
1W Leistung:
-5.45%
1M Leistung:
+11.57%
6M Leistung:
-11.18%
1J Leistung:
+2.46%
1-Tages-Spanne:
$33.07
$33.94
1-Wochen-Bereich:
$33.07
$35.71
52-Wochen-Spanne:
$25.52
$40.87
Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile
Firmenname
Harmony Biosciences Holdings Inc
Sektor
Branche
Telefon
(484) 539-9800
Adresse
630 W GERMANTOWN PIKE, PLYMOUTH MEETING
Compare HRMY vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HRMY
Harmony Biosciences Holdings Inc
|
33.28 | 1.93B | 899.11M | 145.62M | 322.54M | 2.4829 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-23 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2026-02-23 | Herabstufung | Truist | Buy → Hold |
| 2026-02-11 | Fortgesetzt | UBS | Neutral |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-12-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-09-10 | Eingeleitet | UBS | Buy |
| 2024-06-21 | Eingeleitet | Citigroup | Buy |
| 2024-01-02 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-09-25 | Herabstufung | Goldman | Neutral → Sell |
| 2023-09-07 | Eingeleitet | Berenberg | Buy |
| 2023-04-20 | Eingeleitet | BofA Securities | Neutral |
| 2022-10-14 | Hochstufung | Janney | Neutral → Buy |
| 2022-10-14 | Hochstufung | Jefferies | Hold → Buy |
| 2022-08-03 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-13 | Herabstufung | Goldman | Buy → Neutral |
| 2022-07-07 | Eingeleitet | Mizuho | Buy |
| 2022-04-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-12-01 | Eingeleitet | Oppenheimer | Outperform |
| 2021-11-04 | Eingeleitet | Raymond James | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-03-29 | Hochstufung | Goldman | Neutral → Buy |
| 2020-09-14 | Eingeleitet | Goldman | Neutral |
| 2020-09-14 | Eingeleitet | Jefferies | Buy |
| 2020-09-14 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Harmony Biosciences Holdings Inc Aktie (HRMY) Neueste Nachrichten
HRMY Stock On Track For Best Intraday Gains In 18 Months — What Did Mizuho Analysts Say? - Stocktwits
Harmony Biosciences Holdings Inc (HRMY) Institutional Confidence - TradingKey
Harmony Biosciences Holdings Inc (HRMY) Valuation: PE, PB & Fair Value Analysis - TradingKey
Harmony Biosciences Holdings Inc (HRMY) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Harmony Biosciences Holdings Inc (HRMY) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Harmony Biosciences Holdings Inc (HRMY) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Harmony Biosciences Holdings Inc (HRMY) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Harmony Biosciences Holdings Inc - TradingKey
Harmony Biosciences Holdings Inc (HRMY) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Precision Trading with Harmony Biosciences Holdings Inc. (HRMY) Risk Zones - Stock Traders Daily
Wall Street analysts think Harmony Biosciences (HRMY) could surge 34.81%: Read this before placing a bet - MSN
Harmony Biosciences (HRMY) Stock Valuation After New Pitolisant Data And Reaffirmed Guidance - Yahoo Finance
Teva bets $700M on new Tourette syndrome treatment hope - Stock Titan
Harmony Biosciences Announces Poster Presentations at 2026 SLEEP Annual Meeting - Investing News Network
Is Harmony Biosciences Holdings, Inc. (HRMY) A Good Stock To Buy Now? - Insider Monkey
Six narcolepsy and hypersomnia studies from Harmony at SLEEP 2026 - Stock Titan
Harmony Biosciences Holdings Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
HRMY (NASDAQ) affiliate: option exercise 27,960 shares; Kapadia sells 54,646 - Stock Titan
HRMY affiliate files Rule 144 sale notice (NASDAQ: HRMY) for option exercises - Stock Titan
Sandip Kapadia files Form 144 proposing sale of 45,481 HRMY shares (HRMY) - Stock Titan
Technical Reactions to HRMY Trends in Macro Strategies - Stock Traders Daily
Looking Back at Stock Picks Hyatt Hotels, Sensient Technologies, Harmony Biosciences. What the Charts Say. -- Barrons.com - Moomoo
Looking Back at Stock Picks Hyatt Hotels, Sensient Technologies, Harmony Biosciences. What the Charts Say. - Barron's
Harmony Biosciences Holdings (HRMY): One of the Best Stocks to Buy According to AI - Insider Monkey
HRMY or ARGX: Which is the better value stock right now? - MSN
Top 5 US Stocks To Buy In June 2026 - Investing.com
Harmony Biosciences to Participate in Upcoming Investor Conferences - Business Wire
Trading the Move, Not the Narrative: (HRMY) Edition - Stock Traders Daily
H.C. Wainwright reiterates Harmony Biosciences stock rating at buy By Investing.com - Investing.com South Africa
HRMY SEC FilingsHarmony Biosciences Holdings, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
H.C. Wainwright reiterates Harmony Biosciences stock rating at buy - Investing.com
H.C. Wainwright Reiterates Buy Rating on Harmony Biosciences Holdings Inc. (HRMY) - StreetInsider
Harmony Revenue Rises as WAKIX Franchise Expands - MyChesCo
Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities - Quantisnow
A beaten-down biotech just lost a meaningful backer — should you care? - AOL.com
A beaten-down biotech just lost a meaningful backer — should you care? - The Motley Fool
Harmony Biosciences Holdings, Inc.Common Stock (NQ: HRMY - FinancialContent
Harmony Biosciences (HRMY) director Germano Geno J files initial insider Form 3 - Stock Titan
Harmony Biosciences (HRMY) director receives 21,872-share stock option grant - Stock Titan
Harmony Biosciences director granted 21,872 options | HRMY Insider Trading - Stock Titan
Director Graf R. Mark receives 21,872 HRMY stock options in new equity grant - Stock Titan
Harmony Biosciences (HRMY) director awarded 21,872 stock options at $30.76 strike price - Stock Titan
Director Gary Sender receives 21,872 stock options at Harmony Biosciences (HRMY) - Stock Titan
Harmony Biosciences (HRMY) CMO exercises RSUs and covers tax withholding - Stock Titan
Harmony Biosciences (HRMY) CFO granted 164,309 stock options at $29.29 strike - Stock Titan
Harmony Biosciences (HRMY) CFO files initial Form 3 insider report - Stock Titan
Earnings Dip, Revenue Growth and Patent Moves Might Change The Case For Investing In Harmony Biosciences (HRMY) - simplywall.st
Number of shareholders of Harmony Biosciences Holdings, Inc. – NASDAQ:HRMY - TradingView
Harmony Biosciences Shareholders Approve Governance Measures at Meeting - TipRanks
Finanzdaten der Harmony Biosciences Holdings Inc-Aktie (HRMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):